Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma
Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Convergent action on AMR identified as an important area of intervention
Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
Granules now has a total of 58 ANDA approvals from US FDA
Metoprolol Succinate ER Tablets are indicated for the treatment of hypertension in order to lower blood pressure.
Patent Term Extension is designed to restore some of the patent life lost during the regulatory review process for new drugs.
The application is in line with Innocan's strategy to expand the scope of its combined magnesium and cannabis topical solution
Subscribe To Our Newsletter & Stay Updated
